Dr. William M. Schiff, M.D.
Urology (Urology Physician)
7014 N Whitney Ave, Ste A
Fresno, CA 93720
Who else practices at this address →
Fresno County includes primary care (14% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
CA license G502430
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Community Regional Medical Center Fresno, CA
- Clovis Community Medical Center Clovis, CA
- Kaweah Health Medical Center Visalia, CA
- Saint Agnes Medical Center Fresno, CA
- Adventist Health Reedley Reedley, CA
Medical groups
- Urology Associates of Central California Medical Group Inc (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,005
- Services billed
- 26,572
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,200 | 70 |
| Unclassified drugs | 1,798 | 112 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,261 | 613 |
| Ultrasound measurement of bladder capacity after voiding | 981 | 569 |
| Automated urinalysis test | 960 | 603 |
| Established patient office or other outpatient visit, 20-29 minutes | 944 | 588 |
| Insertion of needle into vein for collection of blood sample | 693 | 437 |
| Placement of hormone pellet under skin | 295 | 105 |
| Diagnostic exam of bladder and urethra using an endoscope | 175 | 165 |
| Established patient office or other outpatient visit, 10-19 minutes | 165 | 148 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Fresno, CA | 863 |
| Oxybutynin Chloride Other prescribers in Fresno, CA | 290 |
| Finasteride Other prescribers in Fresno, CA | 272 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Fresno, CA | 126 |
| Testosterone Other prescribers in Fresno, CA | 109 |
| Estradiol Other prescribers in Fresno, CA | 91 |
| Solifenacin Succinate Other prescribers in Fresno, CA | 79 |
| Cephalexin Other prescribers in Fresno, CA | 76 |
| Myrbetriq (mirabegron) Other prescribers in Fresno, CA | 56 |
| Gemtesa (vibegron) Other prescribers in Fresno, CA | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 37 payments worth $991 in total to this clinician.
| Antares Pharma, Inc. | $394 |
|---|---|
| Astellas Pharma US Inc | $168 |
| Boston Scientific Corporation | $92.54 |
| Ferring Pharmaceuticals Inc. | $90.70 |
| Novartis Pharmaceuticals Corporation | $82.76 |
| Bayer HealthCare Pharmaceuticals Inc. | $42.50 |
| Teleflex LLC | $30.19 |
| Profound Medical Corp. | $27.06 |
| Food and Beverage | $823 |
|---|---|
| Education | $168 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Oct 9, 2025 | Education in-kind | $99.99 |
| Astellas Pharma US Inc Aug 12, 2025 | Education in-kind | $68.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $175,436 in research payments for these studies, mostly to the institutions running them.
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232 - Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of The Americas · Recruiting · NCT04757116 - Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374 - A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06545955 - ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Ferring Pharmaceuticals As · Terminated · NCT06026332 - A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
Janssen Research & Development, LLC - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.